CAR-T-терапия in vivo против рака. Как работает метод, результаты испытаний и риски
CAR-T-терапия in vivo против рака. Как работает метод, результаты испытаний и риски SecurityLab.ru
Онкология
Иммунотерапия и CAR-T
185 материалов по теме, собраны автоматически из проверенных источников
Онкология
Онколог рассказал, поможет ли CAR-T-терапия больной раком Лерчек
Онколог рассказал, поможет ли CAR-T-терапия больной раком Лерчек Национальная Служба Новостей
Онкология
Study identifies key drivers of microbiome-linked cancer immunotherapy side effect
Scientists at the University of Pittsburgh uncovered the unstable immune cells that can cause up to 40% of immunotherapy patients to experience serious side effects and showed that diet and microbiome composition influence the side effect's severity.
Онкология
Swim Across America-funded cancer research leads to landmark FDA approval of immunotherapy for rectal cancer
Swim Across America-funded cancer research leads to landmark FDA approval of immunotherapy for rectal cancer EurekAlert!
Онкология
Swim Across America-Funded Cancer Research Leads to Landmark FDA Approval of Immunotherapy for Rectal Cancer
Swim Across America-Funded Cancer Research Leads to Landmark FDA Approval of Immunotherapy for Rectal Cancer EIN Presswire
Онкология
AI identifies tumor aging patterns to predict immunotherapy response across multiple cancer types
Even when given the same drug, some patients respond well while others show little or no response. This is particularly true of immunotherapy. A research team at POSTECH (Pohang University of Science and Technology) has developed an artificial intelligence (AI) technology that can predict, in advance, which patients…
Онкология
Bold Science, Big Questions, a Defining Moment for Cancer Immunotherapy – Agenus
Bold Science, Big Questions, a Defining Moment for Cancer Immunotherapy – Agenus Oncodaily
Онкология
FDA одобрило иммунотерапию для части пациентов с раком прямой кишки — TIME
FDA одобрило иммунотерапию для части пациентов с раком прямой кишки — TIME UA.NEWS
Онкология
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer BioSpace
Онкология
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer Macau Business
Онкология
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer PR Newswire
Онкология
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer PR Newswire
Онкология
David OMalley: Risks of Shorter Steroid Tapers for Severe Immunotherapy Toxicities
David OMalley: Risks of Shorter Steroid Tapers for Severe Immunotherapy Toxicities Oncodaily
Онкология
New drug could let some rectal cancer patients skip chemotherapy, radiation and surgery
Some people with rectal cancer may now be able to skip chemotherapy, radiation and surgery. The U.S. Food and Drug Administration (FDA) on Monday approved the immunotherapy Jemperli (dostarlimab-gxly) for certain adults with rectal cancer that hasn't been treated yet.
🎗️
Онкология
Hillman Cancer Center receives $5M to increase microbiome research, advance immunotherapy cancer treatment
Hillman Cancer Center receives $5M to increase microbiome research, advance immunotherapy cancer treatment The Pitt News